Efficacy and safety of ReDuNing injection as a treatment for COVID-19 and its inhibitory effect against SARS-CoV-2.

"Declaration of competing interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"Acknowledgements and Funding This work was supported by 10.13039/501100012166National Key R&D Program of China (2020YFA0708002), 10.13039/501100001809National Natural Science Foundation of China (82004033), 10.13039/100006180Macao Science and Technology Development Fund (0172/2019/A3, 0042/2020/A), 10.13039/100005930Basic and Applied Basic Research Foundation of Guangdong Province (2020A1515111155), 10.13039/501100002858China Postdoctoral Science Foundation (2020T130028ZX), Guangzhou Science and Technology Bureau key research and development projects (20200804001), Novel Coronavirus Prevention and control Project of Guangdong Province science and Technology Department and Novel Coronavirus Prevention and Control Project of Guangdong Province (2020B111110001, 2020B1111300005, 2020B111112002), 10.13039/501100010226Department of Education of Guangdong Province (2020KZDZX1159), Science Research Project of the Guangdong Province (Nos. 2020B111110001)."

"We enrolled 50 adults with COVID-19 hospitalized in the Lianyungang Fourth People's Hospital affiliated to Kangda College, Nanjing Medical University and The Third People's Hospital of Yichang in China in this study. This was a randomized, open-labeled, multicenter, controlled trial of patients with COVID-19 who met the diagnostic criteria established by the “Diagnosis and Treatment Program for Novel Coronavirus Infection Pneumonia (Trial Fifth Edition).” Patients were enrolled in this study between February 6th and March 23rd, 2020, and the eligibility criteria were as followed: 1) Laboratory-confirmed infection with COVID-19 as established by the National Health Commission (); 2) Presenting as symptomatic (having fever, cough, or fatigue) and exhibiting radiological abnormalities consistent with pneumonia; 3) 18 years or older of either sex. This study was approved by the Ethics Committee at the Tianjin University of Traditional Chinese Medicine and conducted in accordance with GCP guidelines and the Declaration of Helsinki. Written informed consent was obtained from the patients or their legal representatives, and the study was registered with the requisite authorities (ChiCTR2000029589)."